Pharmacokinetics of iloprost in patients with hepatic dysfunction
Hildebrand, M.; Krause, W.; Angeli, P.; Koziol, T.; Gatta, A.; Merkel, C.; Bolognesi, M.
International Journal of Clinical Pharmacology Therapy and Toxicology 28(10): 430-434
1990
ISSN/ISBN: 0174-4879 PMID: 1701761 Document Number: 715
In the present experiment the pharamacokinetics of iloprost was studied in eight hospitalized patients suffering from liver cirrhosis (mean age: 56 years, 3 females, 5 males, child-classification: A [n = 1], B [n = 5], C [n = 2]/mean 14C-aminopyrine breath test: 3.9% dose/2 h). Iloprost was administered as a 1 h-i.v. infusion with 1 ng/kg/min to all the test subjects. Steady state plasma levels of 93 .+-. 31 pg/ml were observed at the end of infusion. The terminal half-life of iloprost was 28 .+-. 24 min. From AUC values of 126 .+-. 60 pg .cntdot. h/ml a total clearance of 10 .+-. 5 ml/min/kg was calculated. The study demonstrated that iloprost clearance was reduced by a factor of 2 in patients suffering from hepatic dysfunction compared with healthy subjects. Individual dose titration is the recommended dose regimen for iloprost therapy in all patients. Therefore, apart from a reduction of the starting dose (of approximately 50%) for titration, special rcommendations are not necessary for patients with impaired liver function.
Document emailed within 1 workday
